Evidence map›Paper›PMID 26924499›Full record

ArticleNuclear medicine and biology2016

(67/68)Galmydar: A metalloprobe for monitoring breast cancer resistance protein (BCRP)-mediated functional transport activity.

Jothilingam Sivapackiam, Scott E Harpstrite, Julie L Prior, Stephen Mattingly, Vijay Sharma

Open access · greenAbstract read
In one paragraph

Article in Nuclear medicine and biology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.0field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. MedChemComm · 2017
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Jothilingam SivapackiamICCE Institute, Molecular Imaging Center, Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, MO 63110, USA.
Scott E HarpstriteICCE Institute, Molecular Imaging Center, Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, MO 63110, USA.
Julie L PriorICCE Institute, Molecular Imaging Center, Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, MO 63110, USA.
Stephen MattinglyICCE Institute, Molecular Imaging Center, Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, MO 63110, USA; Students and Teachers As Research Scientists (STARS), Washington University School of Medicine, St. Louis, MO 63110, USA.
Vijay SharmaICCE Institute, Molecular Imaging Center, Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, MO 63110, USA; Students and Teachers As Research Scientists (STARS), Washington University School of Medicine, St. Louis, MO 63110, USA; Department of Neurology, Washington University School of Medicine, St. Louis, MO 63110, USA; Department of Biomedical Engineering, School of Engineering & Applied Science, Washington University, St. Louis, MO 63105, USA. Electronic address: sharmav@mir.wustl.edu.
Mallinckrodt (United States) · USImaging Center · US

Funding

WASHINGTON UNIVERSITY ALZHEIMERS DISEASE RESEARCH CENTERP50AG005681 · NIA · WASHINGTON UNIVERSITY · PI FAGAN, ANNE · 1985 to 2019
$52.1M
WU-MDACC Inter-Institutional Molecular Imaging CenterP50CA094056 · NCI · WASHINGTON UNIVERSITY · PI PIWNICA-WORMS, DAVID · 2002 to 2016
$26.3M
NOVEL PET AGENT FOR MYOCARDIAL PERFUSION IMAGINGR01HL111163 · NHLBI · WASHINGTON UNIVERSITY · PI SHARMA, VIJAY · 2012 to 2015
$1.5M
IMAGING FUNCTIONAL P-GLYCOPROTEIN TRANSPORT AT THE BBB IN ALZHEIMER'S DISEASER33AG033328 · NIA · WASHINGTON UNIVERSITY · PI SHARMA, VIJAY · 2009 to 2011
$1.1M
NCI NIH HHS CA94056NCI NIH HHS P50 CA094056NHLBI NIH HHS R01 HL111163NIA NIH HHS P50 AG005681NIA NIH HHS P50AG05681NIA NIH HHS R33 AG033328
6 · The paper itself

Abstract

introductionFor stratification of chemotherapeutic choices, radiopharmaceuticals capable of imaging breast cancer resistance protein (BCRP/ABCG2)-mediated functional transport are desired. To accomplish this objective, Galmydar, a fluorescent and moderately hydrophobic Ga(III) cationic complex and its (67/68)Ga-radiolabeled counterparts were interrogated in HEK293 cells stably transfected with BCRP and their WT counterparts transfected with empty vector. Additionally, the sensitivity and specificity of (68)Ga-Galmydar to evaluate functional expression of BCRP at the blood-brain barrier (BBB) was investigated in gene-knockout mdr1a/1b(-/-) (double knockout, dKO) and mdr1a/1b(-/-)ABCG2(-/-) (triple knockout, tKO) mouse models.

methodsFor radiotracer uptake assays and live cell fluorescence imaging, either (67)Ga-Galmydar or its unlabeled counterpart was incubated in HEK293 cells transfected with BCRP (HEK293/BCRP) and their WT counterparts at 37°C under a continuous flux of CO2 (5%) in the presence or absence of Ko143, a potent BCRP antagonist, and cellular uptake was measured to assess the sensitivity of Galmydar to probe BCRP-mediated functional transport activity in cellulo. For assessing the potential of Galmydar to enable diagnostic imaging of targeted tissues in vivo, the (67)Ga-radiolabeled counterpart was incubated in either human serum albumin or human serum at 37°C and the percentage of unbound (67)Ga-Galmydar was determined. To evaluate the sensitivity of (68)Ga-Galmydar for molecular imaging of BCRP-mediated efflux activity in vivo, microPET/CT brain imaging was performed in dKO and tKO mice and their age-matched WT counterparts, 60min post-intravenous injection.

results(67)Ga-Galmydar shows uptake profiles in HEK293 cells inversely proportional to BCRP expression, and antagonist (Ko143) induced accumulation in HEK293/BCRP cells, thus indicating target sensitivity and specificity. Furthermore, employing the fluorescent characteristics of Galmydar, optical imaging in HEK293/BCRP cells shows an excellent correlation with the radiotracer cellular accumulation data. (67)Ga-Galmydar shows > 85% unbound fraction and presence of parental compound in human serum. Finally, microPET/CT imaging shows higher retention of (68)Ga-Galmydar in brains of dKO and tKO mice compared to their age-matched WT counterparts, 60min post-intravenous tail-vein injection.

conclusionsCombined data indicate that Galmydar could provide a template scaffold for development of a PET tracer for imaging BCRP-mediated functional transport activity in vivo.

Indexed as

Gallium RadioisotopesAnimalsATP Binding Cassette Transporter, Subfamily G, Member 2Biological TransportCoordination ComplexesFluorescent DyesHEK293 CellsHumansMaleMiceNeoplasm ProteinsOptical ImagingOrganometallic CompoundsPositron-Emission TomographyRadioactive TracersTomography, X-Ray ComputedABCG2 protein, humanATP Binding Cassette Transporter, Subfamily G, Member 2Coordination Complexes((ENB-3-isopropoxy-PIDMP)Ga(III))Fluorescent DyesGallium RadioisotopesNeoplasm ProteinsOrganometallic CompoundsRadioactive TracersBCRPGalliumMetalloprobe

Identifiers

PMID26924499
PMCPMC12369548
OpenAlexW2192332490

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.